Evolutionarily Diverse LIM Domain-Containing Proteins Bind Stressed Actin Filaments Through a Conserved Mechanism
Total Page:16
File Type:pdf, Size:1020Kb
Load more
Recommended publications
-
Epithelial Protein Lost in Neoplasm a (Eplin-A) Is Transcriptionally Regulated by G-Actin and MAL/MRTF Coactivators
Leitner et al. Molecular Cancer 2010, 9:60 http://www.molecular-cancer.com/content/9/1/60 SHORT COMMUNICATION Open Access Epithelial Protein Lost in Neoplasm a (Eplin-a)is transcriptionally regulated by G-actin and MAL/MRTF coactivators Laura Leitner1, Dmitry Shaposhnikov1, Arnaud Descot1, Reinhard Hoffmann2, Guido Posern1* Abstract Epithelial Protein Lost in Neoplasm a is a novel cytoskeleton-associated tumor suppressor whose expression inver- sely correlates with cell growth, motility, invasion and cancer mortality. Here we show that Eplin-a transcription is regulated by actin-MAL-SRF signalling. Upon signal induction, the coactivator MAL/MRTF is released from a repres- sive complex with monomeric actin, binds the transcription factor SRF and activates target gene expression. In a transcriptome analysis with a combination of actin binding drugs which specifically and differentially interfere with the actin-MAL complex (Descot et al., 2009), we identified Eplin to be primarily controlled by monomeric actin. Further analysis revealed that induction of the Eplin-a mRNA and its promoter was sensitive to drugs and mutant actins which stabilise the repressive actin-MAL complex. In contrast, the Eplin-b isoform remained unaffected. Knockdown of MRTFs or dominant negative MAL which inhibits SRF-mediated transcription impaired Eplin-a expression. Conversely, constitutively active mutant actins and MAL induced Eplin-a. MAL and SRF were bound to a consensus SRF binding site of the Eplin-a promoter; the recruitment of MAL to this region was enhanced sever- alfold upon induction. The tumor suppressor Eplin-a is thus a novel cytoskeletal target gene transcriptionally regu- lated by the actin-MAL-SRF pathway, which supports a role in cancer biology. -
FHL3 Contributes to EMT and Chemotherapy Resistance Through Inhibiting Ubiquitination of Slug and Activating Tgfβ/Smad-Independent Pathways in Gastric Cancer
FHL3 Contributes to EMT and Chemotherapy Resistance Through Inhibiting Ubiquitination of Slug and Activating TGFβ/Smad-Independent Pathways in Gastric Cancer Guodong Cao First Aliated Hospital of Anhui Medical University Pengping Li Hangzhou Xiaoshan No 1 People's Hospital Qiang Sun Xuzhou Medical University Sihan Chen First Aliated Hospital of Anhui Medical University Xin Xu First Aliated Hospital of Anhui Medical University Xiaobo He First Aliated Hospital of Anhui Medical University Zhenyu Wang Hangzhou Xiaoshan No 1 People's Hospital Peng Chen First Aliated Hospital of Anhui Medical University Maoming Xiong ( [email protected] ) First Aliated Hospital of Anhui Medical University Bo Chen First Aliated Hospital of Anhui Medical University Research Keywords: EMT, Chemotherapy resistance, FHL3, Ubiquitination, Gastric cancer Posted Date: October 9th, 2020 DOI: https://doi.org/10.21203/rs.3.rs-87249/v1 License: This work is licensed under a Creative Commons Attribution 4.0 International License. ReLoaadd iFngu l[Ml LaitchJeanxs]/ejax/output/CommonHTML/jax.js Page 1/28 Loading [MathJax]/jax/output/CommonHTML/jax.js Page 2/28 Abstract Background: Gastric cancer presents high risk of metastasis and chemotherapy resistance. Hence, the mechanistic understanding of the tumor metastasis and chemotherapy resistance is quietly important. Methods: TCGA database and clinical samples are used for exploring the role of FHL3 in disease progression and prognosis. The roles of FHL3 in metastasis and chemotherapy resistance are explored in vitro and in vivo by siRNA or shRNA treatment. Finally, we explore the FHL3-mediated EMT and chemotherapy resistance. Results: mRNA and protein level of FHL3 is signicantly up-regulated in gastric cancer tissues when compares with it in adjacent tissue. -
In Vivo Studies Using the Classical Mouse Diversity Panel
The Mouse Diversity Panel Predicts Clinical Drug Toxicity Risk Where Classical Models Fail Alison Harrill, Ph.D The Hamner-UNC Institute for Drug Safety Sciences 0 The Importance of Predicting Clinical Adverse Drug Reactions (ADR) Figure: Cath O’Driscoll Nature Publishing 2004 Risk ID PGx Testing 1 People Respond Differently to Drugs Pharmacogenetic Markers Identified by Genome-Wide Association Drug Adverse Drug Risk Allele Reaction (ADR) Abacavir Hypersensitivity HLA-B*5701 Flucloxacillin Hepatotoxicity Allopurinol Cutaneous ADR HLA-B*5801 Carbamazepine Stevens-Johnson HLA-B*1502 Syndrome Augmentin Hepatotoxicity DRB1*1501 Ximelagatran Hepatotoxicity DRB1*0701 Ticlopidine Hepatotoxicity HLA-A*3303 Average preclinical populations and human hepatocytes lack the diversity to detect incidence of adverse events that occur only in 1/10,000 people. Current Rodent Models of Risk Assessment The Challenge “At a time of extraordinary scientific progress, methods have hardly changed in several decades ([FDA] 2004)… Toxicologists face a major challenge in the twenty-first century. They need to embrace the new “omics” techniques and ensure that they are using the most appropriate animals if their discipline is to become a more effective tool in drug development.” -Dr. Michael Festing Quantitative geneticist Toxicol Pathol. 2010;38(5):681-90 Rodent Models as a Strategy for Hazard Characterization and Pharmacogenetics Genetically defined rodent models may provide ability to: 1. Improve preclinical prediction of drugs that carry a human safety risk 2. -
Bioinformatic Analysis of Structure and Function of LIM Domains of Human Zyxin Family Proteins
International Journal of Molecular Sciences Article Bioinformatic Analysis of Structure and Function of LIM Domains of Human Zyxin Family Proteins M. Quadir Siddiqui 1,† , Maulik D. Badmalia 1,† and Trushar R. Patel 1,2,3,* 1 Alberta RNA Research and Training Institute, Department of Chemistry and Biochemistry, University of Lethbridge, 4401 University Drive, Lethbridge, AB T1K 3M4, Canada; [email protected] (M.Q.S.); [email protected] (M.D.B.) 2 Department of Microbiology, Immunology and Infectious Disease, Cumming School of Medicine, University of Calgary, 3330 Hospital Drive, Calgary, AB T2N 4N1, Canada 3 Li Ka Shing Institute of Virology, University of Alberta, Edmonton, AB T6G 2E1, Canada * Correspondence: [email protected] † These authors contributed equally to the work. Abstract: Members of the human Zyxin family are LIM domain-containing proteins that perform critical cellular functions and are indispensable for cellular integrity. Despite their importance, not much is known about their structure, functions, interactions and dynamics. To provide insights into these, we used a set of in-silico tools and databases and analyzed their amino acid sequence, phylogeny, post-translational modifications, structure-dynamics, molecular interactions, and func- tions. Our analysis revealed that zyxin members are ohnologs. Presence of a conserved nuclear export signal composed of LxxLxL/LxxxLxL consensus sequence, as well as a possible nuclear localization signal, suggesting that Zyxin family members may have nuclear and cytoplasmic roles. The molecular modeling and structural analysis indicated that Zyxin family LIM domains share Citation: Siddiqui, M.Q.; Badmalia, similarities with transcriptional regulators and have positively charged electrostatic patches, which M.D.; Patel, T.R. -
LIMA1 Antibody (N-Term) Blocking Peptide Synthetic Peptide Catalog # Bp16362a
10320 Camino Santa Fe, Suite G San Diego, CA 92121 Tel: 858.875.1900 Fax: 858.622.0609 LIMA1 Antibody (N-term) Blocking Peptide Synthetic peptide Catalog # BP16362a Specification LIMA1 Antibody (N-term) Blocking Peptide LIMA1 Antibody (N-term) Blocking Peptide - - Background Product Information EPLIN is a cytoskeleton-associated protein that Primary Accession Q9UHB6 inhibitsactin filament depolymerization and cross-links filaments inbundles (Maul et al., 2003 [PubMed 12566430]). LIMA1 Antibody (N-term) Blocking Peptide - Additional Information LIMA1 Antibody (N-term) Blocking Peptide - References Gene ID 51474 Chircop, M., et al. Cell Cycle Other Names 8(5):757-764(2009)Abe, K., et al. Proc. Natl. LIM domain and actin-binding protein 1, Acad. Sci. U.S.A. 105(1):13-19(2008)Jiang, Epithelial protein lost in neoplasm, LIMA1, W.G., et al. Mol. Cancer 7, 71 (2008) EPLIN, SREBP3 :Sugiyama, N., et al. Mol. Cell Proteomics 6(6):1103-1109(2007)Olsen, J.V., et al. Cell Format Peptides are lyophilized in a solid powder 127(3):635-648(2006) format. Peptides can be reconstituted in solution using the appropriate buffer as needed. Storage Maintain refrigerated at 2-8°C for up to 6 months. For long term storage store at -20°C. Precautions This product is for research use only. Not for use in diagnostic or therapeutic procedures. LIMA1 Antibody (N-term) Blocking Peptide - Protein Information Name LIMA1 (HGNC:24636) Function Actin-binding protein involved in actin cytoskeleton regulation and dynamics. Increases the number and size of actin stress fibers and inhibits membrane ruffling. Inhibits actin filament depolymerization. -
“Subfossil” Koala Lemur Megaladapis Edwardsi
Evolutionary and phylogenetic insights from a nuclear genome sequence of the extinct, giant, “subfossil” koala lemur Megaladapis edwardsi Stephanie Marciniaka, Mehreen R. Mughalb, Laurie R. Godfreyc, Richard J. Bankoffa, Heritiana Randrianatoandroa,d, Brooke E. Crowleye,f, Christina M. Bergeya,g,h, Kathleen M. Muldooni, Jeannot Randrianasyd, Brigitte M. Raharivololonad, Stephan C. Schusterj, Ripan S. Malhik,l, Anne D. Yoderm,n, Edward E. Louis Jro,1, Logan Kistlerp,1, and George H. Perrya,b,g,q,1 aDepartment of Anthropology, Pennsylvania State University, University Park, PA 16802; bBioinformatics and Genomics Intercollege Graduate Program, Pennsylvania State University, University Park, PA 16082; cDepartment of Anthropology, University of Massachusetts, Amherst, MA 01003; dMention Anthropobiologie et Développement Durable, Faculté des Sciences, Université d’Antananarivo, Antananarivo 101, Madagascar; eDepartment of Geology, University of Cincinnati, Cincinnati, OH 45220; fDepartment of Anthropology, University of Cincinnati, Cincinnati, OH 45220; gDepartment of Biology, Pennsylvania State University, University Park, PA 16802; hDepartment of Genetics, Rutgers University, New Brunswick, NJ 08854; iDepartment of Anatomy, Midwestern University, Glendale, AZ 85308; jSingapore Centre for Environmental Life Sciences Engineering, Nanyang Technological University, Singapore 639798; kDepartment of Anthropology, University of Illinois Urbana–Champaign, Urbana, IL 61801; lDepartment of Ecology, Evolution and Behavior, Carl R. Woese Institute for -
Encapsulation of the Cytoskeleton: Towards Mimicking the Mechanics of a Cell
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
1 Supporting Information for a Microrna Network Regulates
Supporting Information for A microRNA Network Regulates Expression and Biosynthesis of CFTR and CFTR-ΔF508 Shyam Ramachandrana,b, Philip H. Karpc, Peng Jiangc, Lynda S. Ostedgaardc, Amy E. Walza, John T. Fishere, Shaf Keshavjeeh, Kim A. Lennoxi, Ashley M. Jacobii, Scott D. Rosei, Mark A. Behlkei, Michael J. Welshb,c,d,g, Yi Xingb,c,f, Paul B. McCray Jr.a,b,c Author Affiliations: Department of Pediatricsa, Interdisciplinary Program in Geneticsb, Departments of Internal Medicinec, Molecular Physiology and Biophysicsd, Anatomy and Cell Biologye, Biomedical Engineeringf, Howard Hughes Medical Instituteg, Carver College of Medicine, University of Iowa, Iowa City, IA-52242 Division of Thoracic Surgeryh, Toronto General Hospital, University Health Network, University of Toronto, Toronto, Canada-M5G 2C4 Integrated DNA Technologiesi, Coralville, IA-52241 To whom correspondence should be addressed: Email: [email protected] (M.J.W.); yi- [email protected] (Y.X.); Email: [email protected] (P.B.M.) This PDF file includes: Materials and Methods References Fig. S1. miR-138 regulates SIN3A in a dose-dependent and site-specific manner. Fig. S2. miR-138 regulates endogenous SIN3A protein expression. Fig. S3. miR-138 regulates endogenous CFTR protein expression in Calu-3 cells. Fig. S4. miR-138 regulates endogenous CFTR protein expression in primary human airway epithelia. Fig. S5. miR-138 regulates CFTR expression in HeLa cells. Fig. S6. miR-138 regulates CFTR expression in HEK293T cells. Fig. S7. HeLa cells exhibit CFTR channel activity. Fig. S8. miR-138 improves CFTR processing. Fig. S9. miR-138 improves CFTR-ΔF508 processing. Fig. S10. SIN3A inhibition yields partial rescue of Cl- transport in CF epithelia. -
Generation of a Conditional Lima1a Allele in Zebrafish Using the Flex Switch Technology
Generation of a conditional lima1a allele in zebrafish using the FLEx switch technology Peggy Jungke§, Stefan Hans§*, Mansi Gupta, Anja Machate, Daniela Zöller, Michael Brand* Biotechnology Center and Center for Regenerative Therapies Dresden, Dresden University of Technology, Tatzberg 47-49, 01307 Dresden, Germany § Contributed equally. * Corresponding authors: [email protected] [email protected] Running Title: FLEx technology in zebrafish Key words: conditional alleles; FLEx switch; Lima1a; zebrafish 1 Abstract Gene trapping has emerged as a valuable tool to create conditional alleles in various model organisms. Here we report the FLEx-based gene trap vector SAGFLEx that allows the generation of conditional mutations in zebrafish by gene-trap mutagenesis. The SAGFLEx gene trap cassette comprises the rabbit β-globin splice acceptor and the coding sequence of GFP, flanked by pairs of inversely oriented heterotypic target sites for the site-specific recombinases Cre and Flp. Insertion of the gene-trap cassette into endogenous genes can result in conditional mutations that are stably inverted by Cre and Flp, respectively. To test the functionality of this system we performed a pilot screen and analyzed the insertion of the gene-trap cassette into the lima1a gene locus. In this lima1a allele, GFP expression faithfully recapitulated the endogenous lima1a expression and resulted in a complete knockout of the gene in homozygosity. Application of either Cre or Flp was able to mediate the stable inversion of the gene trap cassette and showed the ability to conditionally rescue or reintroduce the gene inactivation. Combined with pharmacologically inducible site specific recombinases the SAGFLEx vector insertions will enable precise conditional knockout studies in a spatial- and temporal-controlled manner. -
Mouse Population-Guided Resequencing Reveals That Variants in CD44 Contribute to Acetaminophen-Induced Liver Injury in Humans
Downloaded from genome.cshlp.org on October 2, 2021 - Published by Cold Spring Harbor Laboratory Press Letter Mouse population-guided resequencing reveals that variants in CD44 contribute to acetaminophen-induced liver injury in humans Alison H. Harrill,1,2,12 Paul B. Watkins,3,12 Stephen Su,6 Pamela K. Ross,2 David E. Harbourt,5 Ioannis M. Stylianou,7 Gary A. Boorman,8 Mark W. Russo,3 Richard S. Sackler,9 Stephen C. Harris,11 Philip C. Smith,5 Raymond Tennant,8 Molly Bogue,7 Kenneth Paigen,7 Christopher Harris,9,10 Tanupriya Contractor,9 Timothy Wiltshire,5 Ivan Rusyn,1,2,14 and David W. Threadgill1,4,13,14,15 1Curriculum in Toxicology, University of North Carolina, Chapel Hill, North Carolina 27599, USA; 2Department of Environmental Sciences and Engineering, University of North Carolina, Chapel Hill, North Carolina 27599, USA; 3Division of Gastroenterology and Hepatology, University of North Carolina, Chapel Hill, North Carolina 27599, USA; 4Department of Genetics, University of North Carolina, Chapel Hill, North Carolina 27599, USA; 5School of Pharmacy, University of North Carolina, Chapel Hill, North Carolina 27599, USA; 6Department of Mouse Genetics, Genomics Institute of the Novartis Research Foundation, San Diego, California 92121, USA; 7The Jackson Laboratory, Bar Harbor, Maine 04609, USA; 8National Institute of Environmental Health Sciences, Research Triangle Park, North Carolina 27709, USA; 9Verto Institute Research Laboratories, New Brunswick, New Jersey 08903, USA; 10Cancer Institute of New Jersey, New Brunswick, New Jersey 08903, USA; 11Purdue Pharma L.P., Stamford, Connecticut 06901, USA; 12Hamner-UNC Center for Drug Safety Sciences, The Hamner Institutes for Health Sciences, Research Triangle Park, North Carolina 27709, USA; 13Department of Genetics, North Carolina State University, Raleigh, North Carolina 27695, USA Interindividual variability in response to chemicals and drugs is a common regulatory concern. -
Functional Genomics Atlas of Synovial Fibroblasts Defining Rheumatoid Arthritis
medRxiv preprint doi: https://doi.org/10.1101/2020.12.16.20248230; this version posted December 18, 2020. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. All rights reserved. No reuse allowed without permission. Functional genomics atlas of synovial fibroblasts defining rheumatoid arthritis heritability Xiangyu Ge1*, Mojca Frank-Bertoncelj2*, Kerstin Klein2, Amanda Mcgovern1, Tadeja Kuret2,3, Miranda Houtman2, Blaž Burja2,3, Raphael Micheroli2, Miriam Marks4, Andrew Filer5,6, Christopher D. Buckley5,6,7, Gisela Orozco1, Oliver Distler2, Andrew P Morris1, Paul Martin1, Stephen Eyre1* & Caroline Ospelt2*,# 1Versus Arthritis Centre for Genetics and Genomics, School of Biological Sciences, Faculty of Biology, Medicine and Health, The University of Manchester, Manchester, UK 2Department of Rheumatology, Center of Experimental Rheumatology, University Hospital Zurich, University of Zurich, Zurich, Switzerland 3Department of Rheumatology, University Medical Centre, Ljubljana, Slovenia 4Schulthess Klinik, Zurich, Switzerland 5Institute of Inflammation and Ageing, University of Birmingham, Birmingham, UK 6NIHR Birmingham Biomedical Research Centre, University Hospitals Birmingham NHS Foundation Trust, University of Birmingham, Birmingham, UK 7Kennedy Institute of Rheumatology, University of Oxford Roosevelt Drive Headington Oxford UK *These authors contributed equally #corresponding author: [email protected] NOTE: This preprint reports new research that has not been certified by peer review and should not be used to guide clinical practice. 1 medRxiv preprint doi: https://doi.org/10.1101/2020.12.16.20248230; this version posted December 18, 2020. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. -
A Glance on the Role of Actin in Osteogenic and Adipogenic
Khan et al. Stem Cell Research & Therapy (2020) 11:283 https://doi.org/10.1186/s13287-020-01789-2 REVIEW Open Access A glance on the role of actin in osteogenic and adipogenic differentiation of mesenchymal stem cells Asmat Ullah Khan† , Rongmei Qu† , Tingyu Fan , Jun Ouyang* and Jingxing Dai* Abstract Mesenchymal stem cells (MSCs) have the capacity to differentiate into multiple lineages including osteogenic and adipogenic lineages. An increasing number of studies have indicated that lineage commitment by MSCs is influenced by actin remodeling. Moreover, actin has roles in determining cell shape, nuclear shape, cell spreading, and cell stiffness, which eventually affect cell differentiation. Osteogenic differentiation is promoted in MSCs that exhibit a large spreading area, increased matrix stiffness, higher levels of actin polymerization, and higher density of stress fibers, whereas adipogenic differentiation is prevalent in MSCs with disrupted actin networks. In addition, the mechanical properties of F-actin empower cells to sense and transduce mechanical stimuli, which are also reported to influence differentiation. Various biomaterials, mechanical, and chemical interventions along with pathogen- induced actin alteration in the form of polymerization and depolymerization in MSC differentiation were studied recently. This review will cover the role of actin and its modifications through the use of different methods in inducing osteogenic and adipogenic differentiation. Keywords: Mesenchymal stem cells (MSCs), Actin, Osteogenesis, Adipogenesis cytoskeleton, Osteogenic differentiation, Adipogenic differentiation, Cytoskeleton Introduction however, this review will focus specifically on the role of Stem cells exhibit a great potential for use in tissue en- actin. gineering because of their regenerative capacity in many Actin is a globular protein with a molecular weight of tissues, including nervous tissue, muscle tissue, adipose approximately 42 kDa and consists of four structural do- tissue, cartilage tissue, and bone tissue.